Eli Lilly's acquisition of Adverum Biotechnologies moved into its final acceptance window Monday as the target company issued a formal reminder to shareholders. The tender offer, announced in October at $13.30 per share in cash, values the gene therapy developer at approximately $900 million. Adverum's board unanimously recommended acceptance. The reminder notice marks standard procedure as offers approach expiration, but timing matters—Lilly structured the deal to close before year-end, leaving minimal buffer.

Adverum brings Lilly a late-stage gene therapy platform focused on ocular diseases, specifically wet age-related macular degeneration. The lead asset, ADVM-022, completed Phase 2 trials with durability data extending beyond 18 months from a single intravitreal injection. Lilly's interest follows its broader push into precision medicine beyond GLP-1 dominance. The company paid a 47% premium to Adverum's 30-day volume-weighted average price at announcement. No competing bids emerged during the go-shop period that ended in late October.

The timing of this reminder notice reveals execution discipline. Tender offers require minimum acceptance thresholds—typically 50.1% of outstanding shares—before buyers can complete the merger. Adverum's institutional ownership sat at 72% as of the last proxy filing, with Deerfield Management holding 14.8% and RA Capital at 11.2%. Both funds specialize in biotech development-stage assets and typically tender into strategic acquisitions at fair premiums. The notice itself carries no new financial terms, but its issuance indicates management has not yet secured the acceptance threshold with certainty.

For allocators, this sequence matters because it telegraphs Lilly's acquisition velocity. The company deployed approximately $4.2 billion in M&A capital through the first three quarters of 2024, including the $2.4 billion Versanis Biosciences deal in June. Adverum represents smaller bolt-on strategy, but the ocular gene therapy market projects to $8.1 billion by 2030. Lilly's willingness to pay development-stage premiums while managing a $550 billion market cap suggests capital allocation flexibility that extends beyond headline obesity franchises.

Watch for the tender offer results in the second week of December, likely disclosed via 8-K filing within four business days of expiration. If acceptance falls short, Lilly may extend the offer by 10 to 20 business days—a maneuver that would push close into January and complicate year-end accounting. Separately, monitor whether Deerfield or RA Capital file Schedule 13D amendments before expiration, as large holder decisions often cascade through smaller institutional positions in final tender windows.

The reminder notice itself is the story. When a $550 billion acquirer needs to prompt shareholders of a $900 million target four weeks after unanimous board recommendation, it signals fragmented retail ownership or arb funds waiting for squeeze premiums that will not materialize. Lilly priced this cleanly. The clock runs out regardless.